Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tarsus Pharmaceuticals excels in Q4 earnings, eyes expansion opportunities

Tarsus Pharmaceuticals delivered strong financial results and positive feedback on their products. While facing challenges in payer contracts and physician adoption, they are well-positioned to capitalize on opportunities for expansion and innovation.

Tarsus Pharmaceuticals reports robust Q1 performance and eyes market expansion

Tarsus Pharmaceuticals (TARS) delivered strong Q1 results driven by XDEMVY sales and positive clinical data, with plans for further growth and optimization. While facing market challenges and seasonality, the company is focused on capitalizing on opportunities for expansion and market education. TARS aims to enhance gross-to-net margins, increase prescriber adoption, and navigate the evolving healthcare landscape.

Tarsus Pharmaceuticals excels in Q3, eyes European expansion and pipeline advancement

Tarsus Pharmaceuticals demonstrated robust performance in Q3 2024, with strong sales, expanded market access, and positive clinical data, positioning the company for continued success.
While facing challenges in market competition and international expansion, Tarsus can capitalize on opportunities in evidence generation, pipeline advancement, and patient education to drive future growth.
Overall, Tarsus Pharmaceuticals shows promise in maintaining its market position, driving product adoption, and exploring new avenues for growth and innovation in the pharmaceutical landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tarsus Pharmaceuticals (TARS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why

TARS has reported positive results from three clinical trials of lotilaner in various formulations. TARS plans to discuss the path forward in these new indications with the US Food and Drug Administration. TARS has also reported sales of $13.1M from the first full quarter of Xdemvy's launch as a treatment for Demodex blepharitis.

Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name

The average of price targets set by Wall Street analysts indicates a potential upside of 37.9% in Tarsus Pharmaceuticals, Inc. (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91%

IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Tarsus will participate in the following conferences:

Tarsus to Participate at Upcoming Investor Conferences

Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease

Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

IRVINE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the pricing of an underwritten public offering of 2,812,500 shares of its common stock at a public offering price of $32.00 per share, and, in lieu of common stock to a certain investor, pre-funded warrants to purchase up to 312,500 shares of its common stock at a public offering price of $31.9999, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 468,750 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Tarsus, are expected to be approximately $100.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close March 5, 2024, subject to the satisfaction of customary closing conditions.

Tarsus Announces Pricing of $100.0 Million Public Offering

IRVINE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the proposed offering. All securities in the proposed offering are to be sold by Tarsus. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Tarsus Announces Proposed $100.0 Million Public Offering

Does Tarsus Pharmaceuticals, Inc. (TARS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy

Tarsus Pharmaceuticals, Inc. (TARS) Q4 2023 Earnings Call Transcript

Launched XDEMVY ® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis and generated fourth quarter net product sales of $13.1 million, and $14.7 million in the first four months since launch

Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements

TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxis TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxis

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease

IRVINE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 5 a.m. PT / 8 a.m. ET on Tuesday, February 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update.

Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024

IRVINE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, will participate in an in-person fireside chat at the Sixth Annual Guggenheim Healthcare Talks conference in New York City at 1:00 p.m. ET on Thursday, February 8, 2024.

Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference

Tarsus Pharmaceuticals, Inc. (TARS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last?

TP-03 demonstrated statistically significant and clinically meaningful improvements across two objective measures of MGD, regardless of BID or TID dosing, and was well tolerated TP-03 demonstrated statistically significant and clinically meaningful improvements across two objective measures of MGD, regardless of BID or TID dosing, and was well tolerated

Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites

AGNC Investment

Crocs

Domino's Pizza

Federated Hermes

Groupon

Gravity Co

Gray TV

Hims & Hers Health

JD.com

Kamada

Malibu Boats

Methanex

OneMain Hld

PayPal

Semrush Holdings

SpringWorks Therapeutics Inc

Tecnoglass

Vanguard S&P 500 ETF

WD-40

Wabash National

In November, we welcomed 24 new analysts who published their first article on Seeking Alpha. This series highlights and welcomes these newcomers to our ranks of analysts who share their unique insights and perspectives as well as some of their top investing ideas. We've compiled all of their firsts here for your review and to showcase the new perspectives being offered on the platform.

Celebrating Seeking Alpha's New Analysts - November 2023 Edition

TARS has launched a new drug, Xdemvy, for the treatment of Demodex blepharitis, with net product sales of $1.7M in the first five weeks following launch. TARS has readouts from three clinical trials due in the next four months, with one due in Q4'23. TARS completed a follow-on offering in August, raising net proceeds of $99.4M. TARS had $246.9M in cash at the end of Q3'23.

Tarsus Pharmaceuticals: 3 Clinical Catalysts In The Next 4 Months, Xdemvy Launch Underway

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants David Nakasone - Head, IR Bobak Azamian - Chairman, CEO Aziz Mottiwala - CCO Jeff Farrow - CFO, CSO Conference Call Participants Jason Gerberry - Bank of America Eddie Hickman - Guggenheim Securities Oren Livnat - H.C. Wainwright Frank Brisebois - Oppenheimer Operator Good afternoon and welcome to the Tarsus Pharmaceuticals Third Quarter 2023 Financial Results Conference Call.

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2023 Earnings Call Transcript

Launched XDEMVY ® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis

Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements

Demodex Blepharitis (DB), Meibomian Gland Dysfunction (MGD), Dry Eye, Rosacea, and Lyme Disease are common conditions that can be treated with XDEMVY™. XDEMVY™ (lotilaner ophthalmic solution 0.25%) is the first FDA-approved treatment for DB and is being investigated for other indications. XDEMVY™ has the potential to capture a significant portion of the market, making it a multibillion-dollar opportunity.

Xdemvy: Tarsus' Leading Asset In A Multi-Billion Market Landscape

IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, November 9, 2023 to report its third quarter 2023 financial results and provide a corporate update.

Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, MD, PhD, Chief Executive Officer and Chairman, will ring the closing bell at the Nasdaq Stock Market on Wednesday, September 6, 2023. The event marks the launch of XDEMVY™, which is now available at pharmacies nationwide for prescription.

Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis

Tarsus Pharmaceuticals has received FDA approval for its lotilaner ophthalmic solution for the treatment of Demodex blepharitis. The company just launched this product known by the brand name Xdemvy and is targeting optometrists and ophthalmologists. Tarsus is also developing lotilaner for the treatment of meibomian gland disease, rosacea, and Lyme's Disease.

Tarsus Pharmaceuticals: Worthy Of A Small Bet

IRVINE, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Strategy Officer, will participate in the following conferences, both located in New York City, NY:

Tarsus to Present at Upcoming Investor Conferences

Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available via prescription from an eye care provider Sales force deployed, calling on ophthalmologists and optometrists nationwide IRVINE, Calif.

News for Tarsus Pharmaceuticals Stock (TARS)